Clinical Research Directory
Browse clinical research sites, groups, and studies.
Autologous Tolerogenic Dendritic Cells (ATDC) for Highly Sensitized Kidney Transplant Recipients
Sponsor: Fundacion Clinic per a la Recerca Biomédica
Summary
The ATDC-PICI study is a Phase Ib, single-arm, prospective, non-randomized, multicentric trial, to evaluate the safety of ATDC cell product as adjunctive therapy to standard of care (SOC) in highly sensitized kidney transplant recipients.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-05
Completion Date
2028-03
Last Updated
2025-02-28
Healthy Volunteers
No
Conditions
Interventions
Autologous Tolerogenic Dendritic Cells
• Autologous Tolerogenic Dendritic Cells (D+1 to D+3 post-transplantation), ATDC, 1 million ATDC/Kg over a period of 30 minutes (up to 1 hour) will administer between Day 1 and Day 3 after transplantation.
Locations (7)
Hospital Germans Trias i Pujol
Badalona, Barcelona, Spain
Hospital del Mar
Barcelona, Barcelona, Spain
Fundació Puigvert
Barcelona, Barcelona, Spain
Hospital Vall d'Hebron
Barcelona, Barcelona, Spain
Hospital Clinic Barcelona
Barcelona, Barcelona, Spain
Hospital Universitari Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Universitario Miguel Servet
Zaragoza, Zaragoza, Spain